Legend Biotech (LEGN) Operating Leases (2019 - 2025)

Legend Biotech has reported Operating Leases for 7 years, with the latest figure at $87.2 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases rose 95.52% year-over-year to $87.2 million; the trailing twelve-month figure through Dec 2025 stood at $87.2 million (up 95.52% YoY), and the FY2025 full-year result was $87.2 million, up 95.52% from the prior year.
• Operating Leases for Q4 2025 stood at $87.2 million, down from $88.1 million in the prior quarter.
• The five-year high for Operating Leases was $88.1 million in Q3 2025, with the low at $2.5 million in Q4 2021.
• Historically, Operating Leases has averaged $48.5 million across 5 years, with a median of $44.5 million in 2023.
• Annual changes were most pronounced in 2021 — Operating Leases dropped 25.76% — and 2022, when it surged 842.57%.
• Legend Biotech's Operating Leases stood at $2.5 million in 2021, then surged by 842.57% to $23.6 million in 2022, then soared by 87.14% to $44.2 million in 2023, then gained by 0.98% to $44.6 million in 2024, then surged by 95.52% to $87.2 million in 2025.
• The last three Operating Leases figures came in at $87.2 million (Q4 2025), $88.1 million (Q3 2025), and $71.7 million (Q2 2025), per Business Quant data.